Delaware jury awards Amgen $70m in patent dispute with Hospira
Amgen has been awarded $70 million in a dispute over a Pfizer subsidiary’s biosimilar of the Epogen treatment for anaemia
A District of Delaware jury
has awarded Amgen $70 million in patent damages against
Pfizer subsidiary Hospira, in a case before Judge Richard
In its verdict, the jury after a five-day trial found
infringement of one of the two...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.